%PDF-1.4
%
59 0 obj
<>
endobj
56 0 obj
<>
endobj
103 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-10-07T09:31:40Z
2024-03-28T22:47:58-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T22:47:58-07:00
application/pdf
Heather
2000-715.nov
uuid:7e90b8e7-1dd2-11b2-0a00-4409278d5b00
uuid:7e90b8e9-1dd2-11b2-0a00-1e0000000000
endstream
endobj
45 0 obj
<>
endobj
46 0 obj
<>
endobj
60 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
21 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
129 0 obj
[133 0 R]
endobj
130 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(4.)-875.1 (Bond )17.7 (WS, Hussar DA. Detection methods and strategies for)]TJ
1.675 -1.25 Td
[(improving medication compliance. )54.8 (Am J Hosp Pharm)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1991;48:1978-88.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (de Klerk E. Measurement of patient compliance on drug therapy)64.8 (.)]TJ
1.675 -1.25 Td
[(In: )17.7 (V)59.8 (ingerhoets )54.8 (A, editor)54.8 (. )54.8 (Advances in behavioral medicine )]TJ
T*
[(assessment. London: Harwood )54.8 (Academic Publishers; 2002:226-6.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Kruse )17.7 (W)91.8 (,)-0.1 ( )17.7 (W)79.9 (eber E. Dynamics of drug regimen compliance \321 its)]TJ
1.675 -1.25 Td
[(assessment by microprocessor)19.7 (-based monitoring. Eur J Clin)]TJ
T*
(Pharmacol 1990;38:561-5.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette )17.7 (VL.)]TJ
1.675 -1.25 Td
[(How often is medication taken as prescribed? )54.8 (A)-220.1 (novel assessment)]TJ
0 Tc T*
[(technique. JAMA)-220.1 (1989;261:3273-7.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Urquhart J, Chevalley C. Impact of unrecognized dosing errors on)]TJ
1.675 -1.25 Td
[(the cost and ef)17.7 (fectiveness of pharmaceuticals. Drug Information J)]TJ
0 Tc 0 Tw T*
(1988;22:363-78.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Feinstein )54.8 (AR. On white-coat ef)17.7 (fects and the electronic monitoring)]TJ
1.675 -1.25 Td
[(of compliance. )54.8 (Arch Intern Med 1990;150:1377-8.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Urquhart J, de Klerk E. Contending paradigms for the interpretation)]TJ
2.175 -1.25 Td
(of data on patient compliance with therapeutic drug regimens. Stat)Tj
0 Tc T*
(Med 1998;17:251-67.)Tj
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Urquhart J. Patient compliance with prescribed drug regimens:)]TJ
2.1381 -1.25 Td
[(overview of the past 30 years of research. In: Nimmo )17.7 (WS, editor)54.8 (.)]TJ
T*
[(Clinical measurement in drug evaluation. New )36.8 (Y)99.8 (ork: John )17.7 (W)39.8 (iley &)]TJ
0 Tc T*
(Sons; 1995:213-27.)Tj
-0.00011 Tc 30.825 28.75 Td
[(12.)-875.1 (Cramer JA, Spilker B, editors. Patient compliance in medical )]TJ
2.175 -1.25 Td
[(practice and clinical trial. New )36.8 (Y)99.8 (ork: Raven Press; 1991.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Metry J, Meyer U. Drug regimen compliance: issues in clinical)]TJ
2.175 -1.25 Td
[(trials and patient management. Chichester: John )17.7 (W)39.9 (iley and Sons;)]TJ
0 Tc 0 Tw T*
(1999.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (de Klerk E, van der Heijde D, Landew\216 R, van der )17.7 (T)69.9 (empel H,)]TJ
2.175 -1.25 Td
(Urquhart J, van der Linden S. Patient compliance in rheumatoid)Tj
T*
(arthritis, polymyalgia rheumatica, and gout. J Rheumatol)Tj
0 Tc 0 Tw T*
(2003;30:44-54.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Peveler R, Geor)17.7 (ge C, Kinmonth )54.8 (AL, Campbell M, )17.7 (Thompson C.)]TJ
2.175 -1.25 Td
[(Ef)17.7 (fect of antidepressant drug counselling and information leaflets)]TJ
T*
(on adherence to drug treatment in primary care: randomised)Tj
T*
(controlled trial. BMJ 1999;319:612-5.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Cramer JA, Rosenheck R. Enhancing medication compliance for)]TJ
2.175 -1.25 Td
(people with serious mental disease. J Nerv Ment Dis )Tj
0 Tc 0 Tw T*
(1999;187:53-4.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Burnier M, Schneider MP)110.7 (, Chiolero )54.8 (A, Fallab CL, Brunner HR.)]TJ
2.175 -1.25 Td
(Objective monitoring of drug compliance: an important step in the)Tj
T*
(management of hypertension resistant to drug therapy [abstract].)Tj
T*
(Am J Hypertens 1999;12:129A.)Tj
/T1_1 1 Tf
-35.4875 -61.0681 Td
[(de Klerk, et al: V)110.7 (alidation of the CQR)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2475)Tj
ET
0 0 0 1 K
55 54 m
559 54 l
S
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
39 0 obj
<>stream
8;Z\4!><7'#ikq,j?)c\$+..dl/nOCEo&pT$RAR("lZpu[XGT>hnRq7p-@Eedk&dj
Mrg'+b'V(\]4PQ7.D[k_@H*SqUQbE%j^$Zk?1H(YjdfGAm(-eG+OU>AF`d@5>,dT.k
[YagMc3RHtSVd+H)`alTn*X(GhYFhT=3nRR>l*Fj.BUK")VY?q?mL2boJ%+P%
Kk.j!.ujJ03a\M_F+Jo$HK^7E^5lC*3!LR?X:pFn`"=VV8<">TXcpr=,TP"f54dLY
?K.!U*5-96^iCcHT0LP+L'i+:F*IEqH9cP3Z`SNt#_F0)Jfk>N+:,i6_N*XjOr_Qk
ebS_tf9Q$d\.&H&J:Bo~>
endstream
endobj
43 0 obj
[/Indexed/DeviceRGB 255 42 0 R]
endobj
42 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
65 0 obj
<>
endobj
62 0 obj
<>
endobj
88 0 obj
<>
endobj
108 0 obj
<>
endobj
63 0 obj
<>
endobj
81 0 obj
<>stream
H{PSWr1"$WGEDZ֭TAtQEBH#!<(@EUq]T|PST]vU:ݨ33}|3spqg_PPК`X([S(}c3,`\fӈ(.qkhM\6_
`$sZNwwM
?\&zh8IޯɅb3)V"MH87ILhP&ooLdt4-F ң:@$+::)nDJ}(N- e}cyaV8^>acg
bytVaK0ފlcqp$*Qh)Қ<:coa_8qZ[Z..P-_走Krŋ.*~X=KZGYODخPVT=۾~b;ơGS(?OGdM1J͢6mC8l _8?߫#U*!/?/'3MAz`
J[*)C:Tf}ꄴ\Y9ٹ3C&GG>C`iV%W=dC?q+狆čʄL";/Ơ<#3e,- Ky2#PAݐѹs1KIC{{A"IMr&'#Nə
Oܬ٧
+NvF
n֍\
XA;X'|:HtS7Ju3B)GRUTeMU'M
l{+֛ɴ5=B2]Zg,irtDkY
8gD8~xW5
%Wp@eNG,ksu'Y^.އ,ʕ]5&D-N"=A Q#0 %ST8SFBqsdu^bd/ʊ
OMPGGynّ|cٳ/gB|p
)QO$i|wҊ4՚7[f=7ʹ{JEPϑu qҍ&DJe<#y!$Sw&FJ(\NAk~;2䴨T+H̬<7=wt/8 F Ovm~ي,`ytztE)/kJQ_82]qيh!f'!)0B]*>ZޖߕΜMZ鍝kv>Aj5dG[ůc͓/,/9KM-65wmR}5l5Q B){ea;
B9w`^ŏ+]njmKؾC~AQ_:&ǃJ̐ql;~Jvrް94UT[_ng_pt
=d36F|)'wr˴h4}$'ڪ"l
9Gw.kB=r]9arFNwQrIrWȯ>3rb:W4G